Literature DB >> 15711732

Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?

Nunzia Montuori1, Valeria Visconte, Guido Rossi, Pia Ragno.   

Abstract

The urokinase-mediated plasminogen activation (PA) system is involved in many physiological and pathological events that include cell migration and tissue remodelling, such as embryogenesis, ovulation, inflammation, wound healing, angiogenesis, and tumor invasion and metastasis. The urokinase receptor (uPAR) is a key molecule of this system and can bind extracellular and cell membrane molecules such as urokinase (uPA), vitronectin (VN), integrins and chemotaxis receptors. These multiple interactions can be modulated by the shedding or the cleavage of the cell membrane receptor. Indeed, cleaved forms of uPAR, lacking the N-terminal D1 domain, have been detected on the surface of cells and in tissues, while soluble forms have been found in biological fluids. Cleaved and soluble forms could represent the intermediary products of the uPAR metabolism or active molecules with precise and distinct functional roles. Here, we review the data concerning the in vitro and in vivo identification of these uPAR forms, their origin and functions, and the role that uPAR shedding and cleavage could play in biological processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711732     DOI: 10.1160/TH04-09-0580

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  33 in total

1.  Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.

Authors:  Audrey M Bernstein; Sally S Twining; Debra J Warejcka; Edward Tall; Sandra K Masur
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

2.  Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.

Authors:  Ceri E Stewart; Ian Sayers
Journal:  Lung       Date:  2013-02-14       Impact factor: 2.584

Review 3.  suPAR: An Inflammatory Mediator for Kidneys.

Authors:  Yashwanth Reddy Sudhini; Changli Wei; Jochen Reiser
Journal:  Kidney Dis (Basel)       Date:  2022-06-08

4.  Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.

Authors:  Juha Onatsu; Mikko Taina; Pirjo Mustonen; Marja Hedman; Antti Muuronen; Otso Arponen; Miika Korhonen; Pekka Jäkälä; Ritva Vanninen; Kari Pulkki
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

5.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

6.  Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.

Authors:  Herbert B Schiller; Andreas Szekeres; Bernd R Binder; Hannes Stockinger; Vladimir Leksa
Journal:  Mol Biol Cell       Date:  2008-11-26       Impact factor: 4.138

7.  Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).

Authors:  Boris K Pliyev
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.396

8.  The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.

Authors:  Dominique Leduc; Nathalie Beaufort; Sophie de Bentzmann; Jean-Claude Rousselle; Abdelkader Namane; Michel Chignard; Dominique Pidard
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

Review 9.  Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization.

Authors:  Caroline A Owen
Journal:  Int J Biochem Cell Biol       Date:  2008-01-31       Impact factor: 5.085

Review 10.  Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.

Authors:  Niaz Mahmood; Shafaat A Rabbani
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.